tranexamic acid has been researched along with Intracranial Aneurysm in 52 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Intracranial Aneurysm: Abnormal outpouching in the wall of intracranial blood vessels. Most common are the saccular (berry) aneurysms located at branch points in CIRCLE OF WILLIS at the base of the brain. Vessel rupture results in SUBARACHNOID HEMORRHAGE or INTRACRANIAL HEMORRHAGES. Giant aneurysms (
Excerpt | Relevance | Reference |
---|---|---|
"A randomized controlled clinical trial was carried out to study the effect of tranexamic acid (AMCA, Cyklokapron; AB Kabi, Stockholm, Sweden) in the prevention of early rebleeding after the rupture of an intracranial aneurysm." | 9.05 | Antifibrinolysis with tranexamic acid in aneurysmal subarachnoid hemorrhage: a consecutive controlled clinical trial. ( Fodstad, H; Forssell, A; Liliequist, B; Schannong, M, 1981) |
"A double-blind clinical trial of tranexamic acid was carried out on 39 patients with fresh subarachnoid hemorrhage from a ruptured aneurysm." | 9.04 | Treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm with tranexamic acid: a double-blind clinical trial. ( Chandra, B, 1978) |
"A randomized, controlled clinical trial was carried out to study the effect of tranexamic acid (AMCA, trans-AMCHA) in prevention of early rebleeding after proven rupture of an intracranial aneurysm." | 9.04 | Tranexamic acid in the preoperative management of ruptured intracranial aneurysms. ( Fodstad, H; Liliequist, B; Schannong, M; Thulin, CA, 1978) |
"In a double-blind controlled clinical trial on 51 patients with subarachnoid hemorrhage, tranexamic acid, 4 gm per day for ten consecutive days, did not favorably affect the outcome." | 9.04 | Effect of tranexamic acid on rebleeding after subarachnoid hemorrhage: a double-blind controlled clinical trial. ( de Jonge, H; Endtz, LJ; Schoen, JH; van Rossum, J; Wintzen, AR, 1977) |
"Among our patients with ruptured intracranial aneurysms 149 were managed pre-operatively with a combination of tranexamic acid (AMCA), 3 gm daily, and aprotinin at an average of 400,000 KIU (Kallikrein inactivating units) daily." | 7.67 | Low-dose tranexamic acid combined with aprotinin in the pre-operative management of ruptured intracranial aneurysms. ( Guidetti, B; Pastore, FS; Rizzo, A; Spallone, A, 1987) |
"The effect of tranexamic acid (TXA) on platelet function was examined in 37 patients with ruptured intracranial aneurysms." | 5.07 | The effect of tranexamic acid on bleeding time and haemostasis. ( Gill, JS; Hartley, JA; Hitchcock, ER; Menzies, SA; Rorke, E, 1991) |
"One hundred patients with a verified subarachnoid haemorrhage were studied in a double blind, placebo-controlled trial at a single centre to determine the value and relative risks of tranexamic acid (TXA) in the management of ruptured intracranial aneurysms." | 5.06 | Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study. ( Hitchcock, ER; Meyer, CH; Tsementzis, SA, 1990) |
"Seventy patients with subarachnoid haemorrhage due to ruptured intracranial aneurysms were managed by delayed intervention (third week) along with the prescription of antifibrinolytic drugs (tranexamic acid 6 g/daily)." | 5.06 | [Prospective trial of treating aneurysmal meningeal hemorrhage by delayed operation under cover of antifibrinolytic therapy]. ( Chabannes, J; Chazal, J; Commun, C; Irthum, B; Janny, P, 1986) |
"We enrolled 479 patients with subarachnoid hemorrhage in a multicenter, randomized, double-blind, placebo-controlled trial to determine whether treatment with the antifibrinolytic agent tranexamic acid improves outcome by preventing rebleeding." | 5.05 | Antifibrinolytic treatment in subarachnoid hemorrhage. ( Cheah, F; Hijdra, A; Lindsay, KW; Muizelaar, JP; Murray, GD; Schannong, M; Teasdale, GM; van Crevel, H; van Gijn, J; Vermeulen, M, 1984) |
"A randomized controlled clinical trial was carried out to study the effect of tranexamic acid (AMCA, Cyklokapron; AB Kabi, Stockholm, Sweden) in the prevention of early rebleeding after the rupture of an intracranial aneurysm." | 5.05 | Antifibrinolysis with tranexamic acid in aneurysmal subarachnoid hemorrhage: a consecutive controlled clinical trial. ( Fodstad, H; Forssell, A; Liliequist, B; Schannong, M, 1981) |
"The outcome of treatment with an antifibrinolytic agent (tranexamic acid) for six weeks after rupture of an intracranial aneurysm was assessed in a randomised controlled trial." | 5.04 | Prolonged antifibrinolysis: an effective non-surgical treatment for ruptured intracranial aneurysms? ( Maurice-Williams, RS, 1978) |
"A double-blind clinical trial of tranexamic acid was carried out on 39 patients with fresh subarachnoid hemorrhage from a ruptured aneurysm." | 5.04 | Treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm with tranexamic acid: a double-blind clinical trial. ( Chandra, B, 1978) |
"A randomized, controlled clinical trial was carried out to study the effect of tranexamic acid (AMCA, trans-AMCHA) in prevention of early rebleeding after proven rupture of an intracranial aneurysm." | 5.04 | Tranexamic acid in the preoperative management of ruptured intracranial aneurysms. ( Fodstad, H; Liliequist, B; Schannong, M; Thulin, CA, 1978) |
"In a double-blind controlled clinical trial on 51 patients with subarachnoid hemorrhage, tranexamic acid, 4 gm per day for ten consecutive days, did not favorably affect the outcome." | 5.04 | Effect of tranexamic acid on rebleeding after subarachnoid hemorrhage: a double-blind controlled clinical trial. ( de Jonge, H; Endtz, LJ; Schoen, JH; van Rossum, J; Wintzen, AR, 1977) |
"To prevent and treat the ischemic complications due to the vasospasm, this report suggest the management of aneurysmal subarachnoid haemorrhage by the association of antifibrinolytics (tranexamic acid) to lower the risk of rebleeding, calcium channel blockers (nimodipine), and the keeping of an effective total blood volume (thanks to volume expansion and dopamine)." | 3.68 | [Evaluation of the treatment of aneurysmal meningeal hemorrhage with antifibrinolytic agents, calcium inhibitors and maintenance of effective blood volume]. ( Berard, JP; Cavaroc, G; Greil, P; Gutknecht, JL; Halberstadt, J; Irthum, B; Planchon, E, 1990) |
"Among our patients with ruptured intracranial aneurysms 149 were managed pre-operatively with a combination of tranexamic acid (AMCA), 3 gm daily, and aprotinin at an average of 400,000 KIU (Kallikrein inactivating units) daily." | 3.67 | Low-dose tranexamic acid combined with aprotinin in the pre-operative management of ruptured intracranial aneurysms. ( Guidetti, B; Pastore, FS; Rizzo, A; Spallone, A, 1987) |
"We previously reported that epsilon-aminocaproic acid (EACA) prolonged the bleeding time in patients with intracranial aneurysms when given in doses of 36 to 48 gm/day." | 3.67 | Clinical and laboratory investigation of the effects of epsilon-aminocaproic acid on hemostasis. ( Atkinson, AJ; Cerullo, L; Cohen, I; Green, D; Ruo, TI; Ts'ao, CH, 1985) |
"Six patients with recently ruptured intracranial aneurysms were treated preoperatively with tranexamic acid (AMCA)." | 3.66 | Determination of tranexamic acid (AMCA) and fibrin/fibrinogen degradation products in cerebrospinal fluid after aneurysmal subarachnoid haemorrhage. ( Fodstad, H; Pilbrant, A; Schannong, M; Strömberg, S, 1981) |
"The occurrence of cerebral ischemia and other complications were recorded, and the effects of treatment were related to the clinical condition on admission." | 2.69 | Antifibrinolytic treatment in subarachnoid hemorrhage: a randomized placebo-controlled trial. STAR Study Group. ( Roos, Y, 2000) |
"Cerebral ischemia was treated with vigorous plasma volume expansion under intermittent monitoring of pulmonary wedge pressure, cardiac output, and arterial blood pressure, aiming for a hematocrit of 0." | 1.30 | Impact of medical treatment on the outcome of patients after aneurysmal subarachnoid hemorrhage. ( Avezaat, CJ; Bijvoet, HW; Hasan, D; Vermeij, FH, 1998) |
"An aneurysm-induced hydrocephalus was observed in two series of patients who were treated antifibrinolytically in different ways: A = 3 g/day of AMCA + 3 - 400,000 KIU/day of aprotinins, B = 6 g/day of AMCA." | 1.27 | Hydrocephalus following aneurysmal SAH. ( Gagliardi, FM; Spallone, A, 1983) |
" The last 20 patients of the present series have been treated with very low doses of AMCA associated with parotid kallikrein inhibitor (Trasylol); this dosage has been effective in preventing recurrence and has appeared to be freer from severe side effects." | 1.26 | The use of antifibrinolytic drugs in aneurysmal subarachnoid hemorrhage. ( Schisano, G, 1978) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 35 (67.31) | 18.7374 |
1990's | 7 (13.46) | 18.2507 |
2000's | 5 (9.62) | 29.6817 |
2010's | 3 (5.77) | 24.3611 |
2020's | 2 (3.85) | 2.80 |
Authors | Studies |
---|---|
Kawada, T | 1 |
Tsai, KC | 1 |
Wu, YH | 1 |
Ho, MP | 1 |
Baharoglu, MI | 1 |
Germans, MR | 1 |
Rinkel, GJ | 1 |
Algra, A | 1 |
Vermeulen, M | 5 |
van Gijn, J | 4 |
Roos, YB | 1 |
Larsen, CC | 1 |
Eskesen, V | 1 |
Hauerberg, J | 1 |
Olesen, C | 1 |
Romner, B | 1 |
Astrup, J | 1 |
Nakaigawa, N | 1 |
Kamata, K | 1 |
Komatsu, R | 1 |
Ozaki, M | 1 |
Lanzino, G | 1 |
Wang, H | 1 |
Iplikçioglu, AC | 1 |
Bek, S | 1 |
Schisano, G | 2 |
Nina, P | 1 |
Roos, Y | 2 |
Guidetti, B | 2 |
Spallone, A | 3 |
Aiba, T | 1 |
Lindsay, KW | 3 |
Murray, GD | 3 |
Cheah, F | 1 |
Hijdra, A | 2 |
Muizelaar, JP | 2 |
Schannong, M | 4 |
Teasdale, GM | 2 |
van Crevel, H | 2 |
Meyer, CH | 3 |
Lowe, D | 1 |
Meyer, M | 1 |
Richardson, PL | 1 |
Neil-Dwyer, G | 3 |
Gagliardi, FM | 1 |
Sharp, MM | 1 |
Sharr, MM | 1 |
Yamaura, A | 1 |
Nakamura, T | 1 |
Makino, H | 1 |
Hagihara, Y | 1 |
Fodstad, H | 7 |
Forssell, A | 2 |
Liliequist, B | 3 |
Ramirez-Lassepas, M | 1 |
Mendelow, AD | 1 |
Stockdill, G | 1 |
Steers, AJ | 1 |
Hayes, J | 1 |
Gillingham, FJ | 1 |
Maurice-Williams, RS | 3 |
Nilsson, IM | 1 |
Pilbrant, A | 1 |
Strömberg, S | 1 |
Gordon, YB | 1 |
Sykes, A | 1 |
Alvarez Garijo, JA | 1 |
Vilches, JJ | 1 |
Aznar, JA | 1 |
Adams, HP | 1 |
Nibbelink, DW | 1 |
Torner, JC | 2 |
Sahs, AL | 1 |
Larsson, C | 1 |
Rönnberg, J | 1 |
Vermeij, FH | 1 |
Hasan, D | 2 |
Bijvoet, HW | 1 |
Avezaat, CJ | 1 |
Stroobandt, G | 1 |
Lambert, O | 1 |
Menard, E | 1 |
Watanabe, H | 1 |
Ito, M | 1 |
Chigasaki, H | 1 |
Ishii, S | 1 |
Chandra, B | 1 |
Thulin, CA | 1 |
Van Rossum, J | 2 |
Wintzen, AR | 2 |
Endtz, LJ | 1 |
Schoen, JH | 1 |
de Jonge, H | 1 |
Check, W | 1 |
Tovi, D | 1 |
Tamaki, N | 1 |
Kusunoki, T | 1 |
Oi, S | 1 |
Taomoto, K | 1 |
Matsumoto, S | 1 |
Tsementzis, SA | 2 |
Hitchcock, ER | 3 |
Menzies, SA | 1 |
Hartley, JA | 1 |
Rorke, E | 1 |
Gill, JS | 1 |
Gutknecht, JL | 1 |
Irthum, B | 2 |
Cavaroc, G | 1 |
Halberstadt, J | 1 |
Planchon, E | 1 |
Greil, P | 1 |
Berard, JP | 1 |
Pastore, FS | 1 |
Rizzo, A | 1 |
Wijdicks, EF | 1 |
Brouwers, PJ | 1 |
Hatfield, R | 1 |
Green, D | 1 |
Ts'ao, CH | 1 |
Cerullo, L | 1 |
Cohen, I | 1 |
Ruo, TI | 1 |
Atkinson, AJ | 1 |
Kassell, NF | 1 |
Haley, EC | 1 |
Chazal, J | 1 |
Commun, C | 1 |
Chabannes, J | 1 |
Janny, P | 1 |
4 reviews available for tranexamic acid and Intracranial Aneurysm
Article | Year |
---|---|
Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage.
Topics: Administration, Oral; Aminocaproic Acid; Antifibrinolytic Agents; Brain Ischemia; Confidence Interva | 2013 |
[The timing of surgical treatment for ruptured intracranial aneurysms--from the viewpoint of intentionally delayed operation (author's transl)].
Topics: Cerebral Hemorrhage; Fibrinolysis; Hemostasis; Humans; Intracranial Aneurysm; Methods; Rupture, Spon | 1981 |
Antifibrinolytic therapy in subarachnoid hemorrhage caused by ruptured intracranial aneurysm.
Topics: Aminocaproates; Aminocaproic Acid; Cyclohexanecarboxylic Acids; Humans; Intracranial Aneurysm; Ruptu | 1981 |
The association of tranexamic acid and nimodipine in the pre-operative treatment of ruptured intracranial aneurysms.
Topics: Adult; Aged; Aged, 80 and over; Aneurysm, Ruptured; Antifibrinolytic Agents; Antihypertensive Agents | 1998 |
17 trials available for tranexamic acid and Intracranial Aneurysm
Article | Year |
---|---|
Antifibrinolytic treatment in subarachnoid hemorrhage.
Topics: Cerebral Angiography; Cerebral Infarction; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Do | 1984 |
Tranexamic acid (AMCA) in aneurysmal subarachnoid haemorrhage.
Topics: Adult; Aged; Brain Ischemia; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Female; Fibrin F | 1980 |
Antifibrinolysis with tranexamic acid in aneurysmal subarachnoid hemorrhage: a consecutive controlled clinical trial.
Topics: Adult; Aged; Brain Ischemia; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Female; Humans; | 1981 |
Double-blind trial of aspirin in patient receiving tranexamic acid for subarachnoid hemorrhage.
Topics: Angiography; Aphasia; Aspirin; Double-Blind Method; Female; Hemiplegia; Humans; Intracranial Aneurys | 1982 |
Coagulation and fibrinolysis in blood and cerebrospinal fluid after aneurysmal subarachnoid haemorrhage: effect of tranexamic acid (AMCA).
Topics: Adult; Aged; Blood Coagulation; Cyclohexanecarboxylic Acids; Female; Fibrin Fibrinogen Degradation P | 1981 |
CT assessment of subarachnoid haemorrhage. A comparison between different CT methods of grading subarachnoid haemorrhage.
Topics: Aneurysm, Ruptured; Cerebral Angiography; Humans; Intracranial Aneurysm; Ischemic Attack, Transient; | 1995 |
Antifibrinolytic treatment in subarachnoid hemorrhage: a randomized placebo-controlled trial. STAR Study Group.
Topics: Adult; Aged; Antifibrinolytic Agents; Brain Ischemia; Calcium Channel Blockers; Drug Therapy, Combin | 2000 |
Prolonged antifibrinolysis: an effective non-surgical treatment for ruptured intracranial aneurysms?
Topics: Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Humans; Intracranial Aneurysm; Recurrence; Ru | 1978 |
Treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm with tranexamic acid: a double-blind clinical trial.
Topics: Adult; Aged; Aminocaproic Acid; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Double-Blind | 1978 |
Tranexamic acid in the preoperative management of ruptured intracranial aneurysms.
Topics: Adult; Aged; Antifibrinolytic Agents; Clinical Trials as Topic; Constriction, Pathologic; Cyclohexan | 1978 |
Antifibrinolytic agents for ruptured intracranial aneurysms.
Topics: Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Double-Blind Method; Humans; Intracranial Ane | 1978 |
Effect of tranexamic acid on rebleeding after subarachnoid hemorrhage: a double-blind controlled clinical trial.
Topics: Aged; Cerebral Angiography; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Double-Blind Meth | 1977 |
Cerebral blood flow in patients with a subarachnoid haemorrhage during treatment with tranexamic acid.
Topics: Adult; Blood Flow Velocity; Cerebrovascular Circulation; Dose-Response Relationship, Drug; Double-Bl | 1992 |
The effect of tranexamic acid on bleeding time and haemostasis.
Topics: Bleeding Time; Blood Coagulation Tests; Drug Administration Schedule; Hemostasis; Humans; Infusions, | 1991 |
Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study.
Topics: Adult; Aged; Brain Ischemia; Cerebrovascular Circulation; Clinical Trials as Topic; Cyclohexanecarbo | 1990 |
Outcome of aneurysmal subarachnoid hemorrhage in patients 66 years of age and older.
Topics: Age Factors; Aged; Aged, 80 and over; Cerebral Infarction; Cyclohexanecarboxylic Acids; Double-Blind | 1988 |
[Prospective trial of treating aneurysmal meningeal hemorrhage by delayed operation under cover of antifibrinolytic therapy].
Topics: Adult; Aged; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Female; Humans; Intracranial Ane | 1986 |
31 other studies available for tranexamic acid and Intracranial Aneurysm
Article | Year |
---|---|
Efficacy and safety of tranexamic acid for aneurysmal subarachnoid hemorrhage.
Topics: Antifibrinolytic Agents; Humans; Intracranial Aneurysm; Subarachnoid Hemorrhage; Tranexamic Acid | 2022 |
Comment on: Tranexamic acid for aneurysmal subarachnoid hemorrhage.
Topics: Humans; Intracranial Aneurysm; Subarachnoid Hemorrhage; Tranexamic Acid | 2022 |
Considerable delay in diagnosis and acute management of subarachnoid haemorrhage.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aneurysm, Ruptured; Antifibrinolytic Agents; Delayed Dia | 2010 |
[Perioperative management of a patient complicated with Quincke's edema].
Topics: Aneurysm, Ruptured; Angioedema; Chlorpheniramine; Craniotomy; Humans; Intracranial Aneurysm; Intubat | 2010 |
Prevention of early rebleeding.
Topics: Antifibrinolytic Agents; Glasgow Outcome Scale; Humans; Intracranial Aneurysm; Multicenter Studies a | 2003 |
Prevention of early rebleeding.
Topics: Antifibrinolytic Agents; Glasgow Outcome Scale; Humans; Intracranial Aneurysm; Multicenter Studies a | 2003 |
Prevention of early rebleeding.
Topics: Aneurysm, Ruptured; Antifibrinolytic Agents; Critical Pathways; Dose-Response Relationship, Drug; Dr | 2003 |
Prevention of early rebleeding.
Topics: Aneurysm, Ruptured; Antifibrinolytic Agents; Brain Ischemia; Glasgow Outcome Scale; Humans; Intracra | 2003 |
The role of antifibrinolytic therapy in the preoperative management of recently ruptured intracranial aneurysms.
Topics: Adult; Antifibrinolytic Agents; Aprotinin; Cyclohexanecarboxylic Acids; Female; Humans; Intracranial | 1981 |
Progressive change in cerebral blood flow during the first three weeks after subarachnoid hemorrhage.
Topics: Adult; Aged; Aging; Blood Pressure; Carbon Dioxide; Cerebrovascular Circulation; Female; Humans; Int | 1983 |
Hydrocephalus following aneurysmal SAH.
Topics: Apoproteins; Drug Therapy, Combination; Humans; Hydrocephalus; Intracranial Aneurysm; Intracranial P | 1983 |
Ruptured intracranial aneurysms.
Topics: Cerebrovascular Circulation; Cyclohexanecarboxylic Acids; Humans; Intracranial Aneurysm; Subarachnoi | 1983 |
Ruptured intracranial aneurysms.
Topics: Cerebrovascular Circulation; Cyclohexanecarboxylic Acids; Humans; Intracranial Aneurysm; Rupture, Sp | 1983 |
Cerebral complication of antifibrinolytic therapy in the treatment of ruptured intracranial aneurysm. Animal experiment and a review of literature.
Topics: Aminocaproates; Aminocaproic Acid; Animals; Blood Pressure; Cerebral Cortex; Cisterna Magna; Cyclohe | 1980 |
Ruptured intracranial aneurysms: has the incidence of early rebleeding been over-estimated?
Topics: Cerebral Angiography; Humans; Intracranial Aneurysm; Ischemic Attack, Transient; Middle Aged; Recurr | 1982 |
Determination of tranexamic acid (AMCA) and fibrin/fibrinogen degradation products in cerebrospinal fluid after aneurysmal subarachnoid haemorrhage.
Topics: Adult; Biotransformation; Cyclohexanecarboxylic Acids; Drug Administration Schedule; Female; Fibrin | 1981 |
Monitoring fibrinolytic activity in the cerebrospinal fluid after aneurysmal subarachnoid haemorrhage: a guide to the risk of rebleeding?
Topics: Brain Neoplasms; Fibrin Fibrinogen Degradation Products; Hemangioma; Humans; Intracranial Aneurysm; | 1980 |
Preoperative treatment of ruptured intracranial aneurysms with tranexamic acid and monitoring of fibrinolytic activity.
Topics: Aminocaproic Acid; Cyclohexanecarboxylic Acids; Fibrin Fibrinogen Degradation Products; Humans; Intr | 1980 |
Antifibrinolytic therapy in patients with aneurysmal subarachnoid hemorrhage. A report of the cooperative aneurysm study.
Topics: Adolescent; Adult; Aged; Aminocaproates; Child; Cyclohexanecarboxylic Acids; Humans; Intracranial An | 1981 |
Impact of medical treatment on the outcome of patients after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Aged; Antifibrinolytic Agents; Brain Ischemia; Female; Hemorrhage; Humans; Hydrocephalus; Int | 1998 |
Antifibrinolytic therapy in ruptured intracranial aneurysm through repeated monitoring of fibrinolytic activity of blood.
Topics: Cyclohexanecarboxylic Acids; Fibrinolysis; Humans; Intracranial Aneurysm; Rupture, Spontaneous; Suba | 1976 |
Spontaneous thrombosis of ruptured intracranial aneurysms during treatment with tranexamic acid (AMCA). Report of three cases.
Topics: Adult; Antifibrinolytic Agents; Female; Humans; Intracranial Aneurysm; Intracranial Embolism and Thr | 1979 |
What about medical therapy alone?
Topics: Antifibrinolytic Agents; Cerebral Hemorrhage; Cyclohexanecarboxylic Acids; Humans; Intracranial Aneu | 1978 |
The use of antifibrinolytic drugs in aneurysmal subarachnoid hemorrhage.
Topics: Adolescent; Adult; Aged; Aminocaproates; Aminocaproic Acid; Cyclohexanecarboxylic Acids; Humans; Int | 1978 |
Proceedings: Preoperative management of patients with aneurysmal subarachnoid haemorrhage. A preliminary comparative study of consecutive and randomized series.
Topics: Cyclohexanecarboxylic Acids; Humans; Intracranial Aneurysm; Recurrence; Subarachnoid Hemorrhage; Tra | 1975 |
[Clinical study on rebleeding of cerebral anuerysms--with special references to the warning signs of rebleeding and antifibrinolytic treatment during waiting time for surgery (author's transl)].
Topics: Adult; Age Factors; Aged; Blood Pressure; Female; Humans; Hypnotics and Sedatives; Intracranial Aneu | 1975 |
[Evaluation of the treatment of aneurysmal meningeal hemorrhage with antifibrinolytic agents, calcium inhibitors and maintenance of effective blood volume].
Topics: Adolescent; Adult; Aged; Cerebral Arterial Diseases; Child; Child, Preschool; Clinical Protocols; Fe | 1990 |
Low-dose tranexamic acid combined with aprotinin in the pre-operative management of ruptured intracranial aneurysms.
Topics: Adult; Aprotinin; Combined Modality Therapy; Cyclohexanecarboxylic Acids; Dose-Response Relationship | 1987 |
Short-term tranexamic acid treatment in aneurysmal subarachnoid hemorrhage.
Topics: Cerebral Angiography; Cyclohexanecarboxylic Acids; Humans; Intracranial Aneurysm; Prospective Studie | 1989 |
Clinical and laboratory investigation of the effects of epsilon-aminocaproic acid on hemostasis.
Topics: Aminocaproates; Aminocaproic Acid; Animals; Aorta, Thoracic; Bleeding Time; Blood Platelets; Cattle; | 1985 |
Antifibrinolytic therapy in the treatment of aneurysmal subarachnoid hemorrhage.
Topics: 4-Aminobenzoic Acid; Aminocaproates; Antifibrinolytic Agents; Humans; Intracranial Aneurysm; para-Am | 1986 |